This bill allows for the legal prescription, distribution, and marketing of crystalline polymorph psilocybin once it is rescheduled by the FDA.

This bill relates to the controlled substance crystalline polymorph psilocybin. It provides that upon the rescheduling of psilocybin by the FDA, it shall be lawful to prescribe, distribute, and market the pharmaceutical composition of crystalline polymorph psilocybin. The bill also removes the drug from schedule I under state law upon its approval by the FDA and rescheduling based on FDA recommendations.

This bill allows for the legal prescription, distribution, and marketing of crystalline polymorph psilocybin once it is rescheduled by the FDA.

This bill relates to the controlled substance crystalline polymorph psilocybin. It provides that upon the rescheduling of psilocybin by the FDA, it shall be lawful to prescribe, distribute, and market the pharmaceutical composition of crystalline polymorph psilocybin. The bill also removes the drug from schedule I under state law upon its approval by the FDA and rescheduling based on FDA recommendations.